Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
An Open-Label, Dose Escalation, Multi-Center Phase I/II Research Trial to Assess the Safety of ET140203 T Cells and Determine the Recommended Phase II Dose RP2D in Adults with Advanced Hepatocellular Carcinoma HCC who are not Candidates for Standard-Of-Care Therapy.
Bladder Cancer Longitudinal Biorepository for Development of Novel Therapeutics/Biomarkers
A Phase I Study to Evaluate the Pharmacokinetics and Safety of Belantamab Mafodotin Monotherapy in Participants with Relapsed and/or Refractory Multiple Myeloma RRMM Who Have Normal and Varying Degrees of Impaired Renal Function DREAMM 12
A Phase I-A Study Evaluating the Safety, Tolerability and Preliminary Efficacy of IBI322 In Subjects with Advanced Malignant Tumors
Randomized IIB Study of the Effect of Bazedoxifene plus Conjugated Estrogens on Breast Imaging and Tissue Biomarkers in Peri or Post-Menopausal Women at Increased Risk for Development of Breast Cancer
A Phase IIIb, Randomized, Multicenter, Open-label Study to assess the Efficacy of Durvalumab plus Tremelimumab versus Pembrolizumab in Combination with Platinum-Based Chemotherapy for First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with Non-Squamous Histology who have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS TRITON
A Multi-national, Multi-center, Open-label, Phase II Clinical Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of DHP107 Liporaxel, Oral Paclitaxel Compared to IV Paclitaxel in Patients with Recurrent or Metastatic Breast Cancer
A Phase IIa Study with Safety Run-in to Evaluate the Safety, Tolerability, and Preliminary Efficacy of FF-10832 Monotherapy or in Combination with Pembrolizumab in Patients with Advanced Solid Tumors
Study Type: Treatment
Phase: II
NCTID: NCT05318573
Principal Investigator:
Haoran Li
A Randomized Phase III Study of MRTX849 versus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation
Study Type: Treatment
Phase: III
NCTID: NCT04685135
Principal Investigator:
Jun Zhang